MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 565000 | Name: SV119

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SV119 is a selective sigma-2 (σ₂) receptor ligand that has demonstrated notable bioactivity, particularly in cancer models. It binds the sigma-2 receptor with high affinity (reported Ki ≈ 5–10 nM) and shows >100-fold selectivity over sigma-1 (σ₁) receptors. In vitro, SV119 induces apoptosis in a range of human cancer cell lines, including breast, prostate, and pancreatic cancers, by activating caspase-3 and promoting mitochondrial depolarization. Importantly, SV119 can potentiate the effects of chemotherapeutic agents such as paclitaxel or doxorubicin, enhancing cytotoxicity in tumor cells while sparing normal tissues. In vivo studies in murine xenograft models have shown that SV119 accumulates in tumor tissue and can significantly reduce tumor growth when used alone or in combination therapy.

Chemical Structure

SV119
SV119
CAS#913815-82-4 (free base)

Theoretical Analysis

MedKoo Cat#: 565000

Name: SV119

CAS#: 913815-82-4 (free base)

Chemical Formula: C23H37N3O3

Exact Mass: 403.2835

Molecular Weight: 403.57

Elemental Analysis: C, 68.45; H, 9.24; N, 10.41; O, 11.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
913815-82-4 (free base) 913816-12-3 (HCl)
Synonym
SV-119; SV 119; SV119
IUPAC/Chemical Name
(1R,3r,5S)-9-(6-Aminohexyl)-9-azabicyclo[3.3.1]nonan-3-yl (2-methoxy-5-methylphenyl)carbamate
InChi Key
LKFLCBUCBHTSTF-PMOLBWCYSA-N
InChi Code
InChI=1S/C23H37N3O3/c1-17-10-11-22(28-2)21(14-17)25-23(27)29-20-15-18-8-7-9-19(16-20)26(18)13-6-4-3-5-12-24/h10-11,14,18-20H,3-9,12-13,15-16,24H2,1-2H3,(H,25,27)/t18-,19+,20+
SMILES Code
O=C(O[C@H]1C[C@@](N2CCCCCCN)([H])CCC[C@@]2([H])C1)NC3=CC(C)=CC=C3OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 403.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Takchi R, Prudner BC, Gong Q, Hagi T, Newcomer KF, Jin LX, Vangveravong S, Van Tine BA, Hawkins WG, Spitzer D. Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress. Cell Death Dis. 2024 May 2;15(5):309. doi: 10.1038/s41419-024-06693-8. PMID: 38697978; PMCID: PMC11066049. 2: McDonald ES, Mankoff J, Makvandi M, Chu W, Chu Y, Mach RH, Zeng C. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells. Biochem Biophys Res Commun. 2017 May 6;486(3):788-795. doi: 10.1016/j.bbrc.2017.03.122. Epub 2017 Mar 24. PMID: 28347815. 3: Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget. 2016 Jun 7;7(23):33529-41. doi: 10.18632/oncotarget.9551. PMID: 27244881; PMCID: PMC5085100. 4: Sun T, Wang Y, Wang Y, Xu J, Zhao X, Vangveravong S, Mach RH, Xia Y. Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies. Adv Healthc Mater. 2014 Aug;3(8):1283-91. doi: 10.1002/adhm.201400026. Epub 2014 Mar 26. PMID: 24677807; PMCID: PMC4134721. 5: Zhang P, Huang Y, Makhov AM, Gao X, Zhang P, Li S. Characterization of spherulites as a lipidic carrier for low and high molecular weight agents. Pharm Res. 2013 Jun;30(6):1525-35. doi: 10.1007/s11095-013-0990-y. Epub 2013 Apr 12. PMID: 23579481; PMCID: PMC3654020. 6: Zhang Y, Huang Y, Zhang P, Gao X, Gibbs RB, Li S. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells. Int J Nanomedicine. 2012;7:4473-85. doi: 10.2147/IJN.S31981. Epub 2012 Aug 13. PMID: 22927761; PMCID: PMC3422102. 7: Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, Tu Z, Pan F, Chang KC, Hotchkiss R, Mach RH. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Cancer. 2012 Feb 14;106(4):693-701. doi: 10.1038/bjc.2011.602. Epub 2012 Jan 17. PMID: 22251921; PMCID: PMC3322954. 8: Wang Y, Xu J, Xia X, Yang M, Vangveravong S, Chen J, Mach RH, Xia Y. SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptors. Nanoscale. 2012 Jan 21;4(2):421-4. doi: 10.1039/c1nr11469g. Epub 2011 Nov 24. PMID: 22113350; PMCID: PMC4600571. 9: Spitzer D, Simon PO Jr, Kashiwagi H, Xu J, Zeng C, Vangveravong S, Zhou D, Chang K, McDunn JE, Hornick JR, Goedegebuure P, Hotchkiss RS, Mach RH, Hawkins WG. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer- selective cell death signaling. Cancer Res. 2012 Jan 1;72(1):201-9. doi: 10.1158/0008-5472.CAN-11-1354. Epub 2011 Nov 7. PMID: 22065721; PMCID: PMC3251632. 10: Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer. 2010 Nov 22;9:298. doi: 10.1186/1476-4598-9-298. PMID: 21092190; PMCID: PMC3106998. 11: Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG. Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med. 2009 Mar 26;7:24. doi: 10.1186/1479-5876-7-24. PMID: 19323815; PMCID: PMC2669042. 12: Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007 Jul 15;6:48. doi: 10.1186/1476-4598-6-48. PMID: 17631687; PMCID: PMC1939854.